BIOPIX-T was founded in December 2019 in order to commercialize a novel molecular diagnostic device, branded as IRIS, for the detection of nucleic acids at the point-of-care. IRIS introduces a radical improvement in genetic testing allowing for the first time the combination of affordability and portability with the accuracy and sensitivity of standard lab-based molecular diagnostic tools.

Read more about our investment in BIOPIX-T here.